GENERAL HOSPITAL OF KARDITSA
- Address
- Terminal of Tavropos, 43100 Karditsa, Greece
GENERAL HOSPITAL OF KARDITSA - Ophthalmology and Glaucoma Research
The General Hospital of Karditsa has established expertise in ophthalmological research, with a particular focus on clinical trials evaluating treatments for glaucoma and ocular hypertension. The center specializes in conducting comparative efficacy studies and non-inferiority trials for intraocular pressure (IOP) management therapies, contributing valuable evidence for generic pharmaceutical formulations in ophthalmology.
- Fixed-combination eye drop formulations for glaucoma management
- Open angle glaucoma and ocular hypertension treatment optimization
- Generic versus reference product equivalence studies
The research center has demonstrated capability in conducting rigorous clinical evaluations of multiple topical ophthalmic agents, including combination therapies with brinzolamide, timolol, and brimonidine. These studies focus on measuring diurnal IOP changes and assessing the clinical non-inferiority of new formulations, ultimately contributing to expanded therapeutic options for patients with elevated intraocular pressure and supporting cost-effective treatment alternatives in glaucoma care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in GENERAL HOSPITAL OF KARDITSA
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Non-Inferiority Trial of Brimonidine Tartrate/Timolol Maleate Eye Drops Versus Combigan in Open-Angle Glaucoma or Ocular Hypertension Patients | Becro (Cyprus) Limited | Phase III | Not Recruiting | May 2024 | Feb 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Brimonidine Tartrate | 1 | Unknown | 2024-05-31 | 2024-05-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.